Insulin Biosimilars Market, By Biosimilar Type (Rapid-acting Biosimilars, Long-acting Biosimilars, and Premixed Biosimilars), By Disease Indication Type (Type 1 Diabetes and Type 2 Diabetes), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

Report Code: PMI4618 | Publish Date: May 2022 | No. of Pages: 156

Global Insulin Biosimilars Market By Overview

Biosimilars are the complex biologic medicine made from living cells, which must be handled and administered under carefully monitored conditions. Biosimilar is a copy of another FDA approved biologic drug also known as reference product. Group of metabolic disease diabetes; is characterized by high blood sugar level owing to inadequate insulin secretion. Diabetes is a type of metabolic disease which has occurred in many individuals due to high blood sugar level owing to inappropriate secretion of insulin. Insulin Biosimilar are primarily used to balance sugar level of the blood. Biosimilar insulin is designed to be highly similar to the original insulin product but not identical manufacturing technique than what the original patent holder used. Insulin Biosimilar is similar to generic forms of small molecule drugs and is produced by companies other than the reference products patent holder.Global Insulin Biosimilar Market accounted for US$ 2.14 billion in 2020 and is estimated to be US$ 3.65 billion by 2030 and is anticipated to register a CAGR of 5.52%

Global Insulin Biosimilars Market By Dynamics

Increasing prevalence of diabetes

Increasing prevalence of diabetes across the globe is major factor driving growth of the global Insulin Biosimilar market. For instance, in 2018, according to data published by World Health Organization (WHO), the number of people with diabetes has risen from 108 Mn in 1980 to 422 Mn in 2014. In addition, growing number of manufacturers developing Insulin Biosimilar with lower price than others generic insulin manufacturers are factors augmenting the growth of global Insulin Biosimilar market. Furthermore, increasing novel product launches and approval supports from regulatory bodies for new products fosters the global Insulin Biosimilar market. For instance, in 2016, Food Drug Administration (FDA) has approved new insulin glargine Basaglar, for type 1 and type 2 diabetes which is biosimilar version of Sanofi’s basal insulin Lantus. Key players are also focused on designing advanced Insulin Biosimilar that allows less painful and safe delivery to the patients. This factor expected to promote growth of the global Insulin Biosimilar market in near future. Growing healthcare sector across the globe is expected to spur growth of the global Insulin Biosimilar market in near future. However, insulin patent protection rights and strong retaliation from the branded manufactures is expected to hamper growth of the global Insulin Biosimilar market.

 

With changes in formulations of drug is major factor expected to hamper growth of the target market over the forecast period.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Insulin Biosimilars Market By Segmentation

 

Global Insulin Biosimilar market is segmented on the basis of biosimilar type, disease indication, and geography.

On the basis of type, the global insulin biosimilar has been segmented into rapid acting biosimilar, long acting biosimilars, and premixed biosimilars. On the basis of disease indication the global insulin biosimilar market is segmented into type 1 diabetes, and type 2diabetes. On the basis of region, the target market has been segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is expected to account major market share as compared to that of other regions.

Regional Insights:

                                      

 

For detailed understanding of market dynamics, the global Insulin Biosimilar market is analyzed across key regions viz North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the global market. In 2018, North America market dominated the global Insulin Biosimilar market due to high prevalence of diabetes in this region which turns into high demand for insulin. Further, Europe Insulin Biosimilar market is expected to account for second largest revenue share in the global market due to early approval for Insulin Biosimilar in the countries of the region. Asia Pacific market is expected to witness fastest growth in terms of revenue over the forecast period. This is attributed to key players competing on the basis of price and further the increased number of patient pool suffering diabetes in the countries of this region fosters the Insulin Biosimilar market in Asia Pacific region.

 

                                   

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Report Scope:

Attribute

Details

Base year for estimation

2020

Forecast period

2020 – 2029

Market representation

Revenue in USD Million & CAGR from 2020 – 2029

Market Segmentation

By Biosimilar-Type- Rapid Acting Biosimilar, Long Acting Biosimilar, And Premixed Biosimilar

By Disease Indication Type- Type 1 Diabetes, And Type 2 Diabetes

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

 

Global Insulin Biosimilar Market, By Biosimilar Type:

      • Rapid acting biosimilar
      • Long acting biosimilar
      • Premixed biosimilar

Global Insulin Biosimilar Market, By Disease Indication Type:

      • Type 1 diabetes
      • Type 2 diabetes

Global Insulin Biosimilar Market, By Region:

      • North America
        • North America Insulin Biosimilar Market, By Biosimilar Type
        • North America Insulin Biosimilar Market, By Disease Indication Type
        • North America Insulin Biosimilar Market, By Country
          • U.S.
          • Canada
      • Europe
        • Europe Insulin Biosimilar Market, By Biosimilar Type
        • Europe Insulin Biosimilar Market, By Disease Indication Type
        • Europe Insulin Biosimilar Market, By Country
          • Germany
          • UK
          • France
          • Russia
          • Italy
          • Rest of Europe
      • Asia Pacific
        • Asia Pacific Insulin Biosimilar Market, By Biosimilar Type
        • Asia Pacific Insulin Biosimilar Market, By Disease Indication Type
        • Asia Pacific Insulin Biosimilar Market, By Country
          • China
          • India
          • Japan
          • South Korea
          • Rest of Asia Pacific
      • Latin America
        • Latin America Insulin Biosimilar Market, By Biosimilar Type
        • Latin America Insulin Biosimilar Market, By Disease Indication Type
        • Latin America Insulin Biosimilar Market, By Country
          • Brazil
          • Mexico
          • Rest of Latin America
      • Middle East & Africa
        • Middle East & Africa Insulin Biosimilar Market, By Biosimilar Type
        • Middle East & Africa Insulin Biosimilar Market, By Disease Indication Type
        • Middle East & Africa Insulin Biosimilar Market, By Country
          • GCC
          • Israel
          • South Africa
          • Rest of Middle East & Africa

Global Insulin Biosimilars Market By Key Players

Some of the prominent players operating in the global Insulin Biosimilar market include Boehringer Ingelheim GmbH, Pfizer Inc., Biocon Ltd., Merck & Co., Mylan N.V., Eli Lilly & Co., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A., and Ypsomed Holding AG. Advancements in the product as well as in manufacturing process, product launches, and strategic partnerships are some trends witnessed in the global Insulin Biosimilar market. For instance, in 2018, Eli Lilly and Company and Boehringer Ingelheim received approval for biosimilar insulin named glargine through European Medicines Agency's (EMA's) biosimilar pathway.

Market Taxonomy:

This report segments the global Insulin Biosimilar market on the basis of biosimilar type, disease indication type, and region. On the basis of biosimilar type, the global Insulin Biosimilar has been segmented into rapid acting biosimilar, long acting biosimilar, and premixed biosimilar. Based on disease indication type, the target market is bifurcated into type 1 diabetes, and type 2 diabetes. Segment type 2 diabetes is expected to hold highest market share in terms of revenue as compared to segment type 2 diabetes over the forecast period. This is attributed to type 2 diabetes comprises the majority of people with diabetes across the globe.

Key features of the study:

Prophecy Market Insights provides detailed analysis on Insulin Biosimilar market in our report- Global Insulin Biosimilar Market by biosimilar type, disease indication type, and region. The report provides market size (US$ Mn) and compounded annual growth rate (%) for the forecast period: 2019 – 2029, considering 2018 as the actual year. The report also contains in-depth analysis about market drivers, restraints, opportunities, new product launches, product approval, ongoing trends, customers demand, and regional outlook. The report delivers competitive analysis about leading players in the global Insulin Biosimilar market based on various parameters such as company overview, product portfolio, regional presence, financial performance, distribution strategies, key developments, marketing strategies, and future plans. The analysis from the report would acquaint the marketers and management authorities of companies to make the appropriate decision with respect to their future product launch, ongoing trends, market expansion, and marketing tactics used overall the globe. Various strategy matrices include in the report are PEST analysis, PORTER’s five forces analysis, and opportunity map analysis to analyze the Insulin Biosimilar market.

Global Insulin Biosimilars Market By Company Profile

          • Boehringer Ingelheim GmbH
            • Company Overview
              • Product Portfolio
              • Key Highlights
              • Financial Performance
            • Ypsomed Holding AG
              • Company Overview
              • Product Portfolio
              • Key Highlights
              • Financial Performance
            • Sanofi S.A.
              • Company Overview
              • Product Portfolio
              • Key Highlights
              • Financial Performance
            • NOVO Nordisk A/S
              • Company Overview
              • Product Portfolio
              • Key Highlights
              • Financial Performance
            • Wockhardt Limited
              • Company Overview
              • Product Portfolio
              • Key Highlights
              • Financial Performance
            • Eli Lilly & Co.
              • Company Overview
              • Product Portfolio
              • Key Highlights
              • Financial Performance
            • Mylan N.V.
              • Company Overview
              • Product Portfolio
              • Key Highlights
              • Financial Performance
            • Merck & Co, Inc
              • Company Overview
              • Product Portfolio
              • Key Highlights
              • Financial Performance
            • Biocon Limited
              • Company Overview
              • Product Portfolio
              • Key Highlights
              • Financial Performance
            • Pfizer Inc.
              • Company Overview
              • Product Portfolio
              • Key Highlights
              • Financial Performance

Global Insulin Biosimilars Market By Table of Contents

  • Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  • Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  • Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Insulin Biosimilar Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Biosimilar Type
      • Market Snippet, By Disease Indication Type
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  • Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  • Global Insulin Biosimilar Market, By Biosimilar type, 2020 – 2030, (US$ Mn)
    • Rapid-Acting Biosimilars  
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Segment Trends
    • Long-Acting Biosimilar
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Pre-mixed Biosimilar
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  • Global Insulin Biosimilar Market, By Disease Indication Type, 2020 – 2030, (US$ Mn)
    • Type I Diabetes
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
    • Type II Diabetes
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
  • Global Insulin Biosimilar Market, By Region, 2020 – 2030, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
      • Y-o-Y Growth Analysis (%), 2020 – 2030
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Biosimilar type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Disease Indications Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Biosimilar type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Disease Indications Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Biosimilar type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Disease Indications Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Biosimilar type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Disease Indications Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Biosimilar type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Disease Indications Type, 2020 – 2030
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  • Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  • Company Profiles
      • Boehringer Ingelheim GmbH
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
      • Biocon Limited
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
      • Merck & Co, Inc
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
      • Eli Lilly & Co.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
      • Wockhardt Limited
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
      • NOVO Nordisk A/S
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
      • Ypsomed Holding AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance

The Last Word

    • Future Impact
    • About Us
    • Contact

FAQs

Global Insulin Biosimilar market is segmented on the basis of biosimilar type, disease indication, and geography.

Increasing prevalence of diabetes is major factor expected to propel growth of the insulin biosimilars market over the forecast period. Further, increasing investment by key players in manufacturing and developing the biosimilar insulin to provide the similar clinical aid in cost effective way increases the demands of insulin biosimilar in the market.

North America is expected to account major market share as compared to that of other regions.

Key players operating in the global market of insulin biosimilar Boehringer Ingelheim, Pfizer Inc., Biocon, Merck & Co., Mylan N.V., Eli Lilly & Co., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A., and Ypsomed AG.